Microgyn (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, together with levonorgestrel, suppresses the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This inhibition prevents ovulation, while the progestin component thickens cervical mucus and alters the endometrium, reducing the chance of implantation.

The dosing regimen for Microgyn is determined by the prescribing clinician. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule should follow the prescriber’s instructions.

Microgyn is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data exist for breastfeeding; clinicians usually advise against use while nursing unless the benefits outweigh potential risks.

To order Microgyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgyn contains the standard estrogen (ethinylestradiol) and a third‑generation progestin (levonorgestrel). Compared with older formulations, it offers similar contraceptive efficacy but may have a different side‑effect profile, such as a slightly lower risk of androgenic effects while maintaining comparable protection against pregnancy.

Microgyn tablets should be stored at room temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Microgyn is taken orally, usually once each day at the same time. The tablets are swallowed with water and should be started on the first day of the menstrual period or as directed by a healthcare professional.

The most serious risks include venous thromboembolism, stroke, myocardial infarction, and severe allergic reactions such as anaphylaxis. Patients with a history of clotting disorders, smoking, or certain cardiovascular conditions should be evaluated carefully before starting therapy.

Microgyn is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over age 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.